GlassScriptPhysician profile
Prativa Rajbhandari
NPI 1659628667
$2,603.13
in general payments reported to CMS, 2019-2025
25 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.49 · 2023: $290 · 2024: $1,222 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483 · Gift: $42.50 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,482.64 |
| Gift | $42.50 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $655.03 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $380.93 | 2023-2025 | Ozempic, Rybelsus, Saxenda |
| Insulet Corporation | $151.58 | 2023-2025 | Omnipod |
| Medtronic, INC. | $135.52 | 2024 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.91 | 2024 | Jardiance |
| Mannkind Corporation | $127.43 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $111.76 | 2024 | |
| Dexcom, INC. | $106.30 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $98.93 | 2024-2025 | |
| Sequel Med Tech, LLC | $96.68 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $64.43 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Regeneron Healthcare Solutions, INC. | $57.05 | 2022-2023 | Praluent, Evkeeza |
| Recordati_rare_diseases_inc. | $52.86 | 2024 | Isturisa, Signifor Lar |
| Ionis Pharmaceuticals, INC. | $52.44 | 2025 | Tryngolza |
| Ibsa Pharma INC. | $51.76 | 2025 | Tirosint, Flector, Licart |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $51.05 | 2025 | Teriparatide |
| Corcept Therapeutics | $50.14 | 2023-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $47.44 | 2025 | Recorlev |
| Amgen INC. | $45.12 | 2025 | Tepezza |
| Abbott Laboratories | $40.09 | 2025 | Freestyle Libre 3 |
| Radius Health, INC. | $21.15 | 2024 | Tymlos |
| Beta Bionics, INC. | $20.93 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tolmar, INC. | $19.26 | 2025 | Jatenzo |
| Ascensia Diabetes Care US INC. | $18.33 | 2025 | |
| Alexion Pharmaceuticals, INC. | $14.01 | 2024 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prativa Rajbhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.